Compare GLBS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | ATOS |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 36.2M |
| IPO Year | 2010 | 2010 |
| Metric | GLBS | ATOS |
|---|---|---|
| Price | $2.75 | $2.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $23.00 |
| AVG Volume (30 Days) | 234.7K | ★ 260.4K |
| Earning Date | 06-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | $13.06 | N/A |
| Revenue Next Year | $20.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.53 |
| 52 Week High | $3.24 | $7.56 |
| Indicator | GLBS | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 36.59 |
| Support Level | $1.51 | $0.58 |
| Resistance Level | $3.21 | $2.60 |
| Average True Range (ATR) | 0.22 | 0.17 |
| MACD | -0.06 | 0.15 |
| Stochastic Oscillator | 14.66 | 64.44 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.